(This November 8 story corrects spelling of analytics firm ESGauge, paragraph 10) By Tim McLaughlin BOSTON (Reuters) - It's nice work if you can get it. The average annual...
The company reported third-quarter 2019 operating results and raised full-year 2019 guidance for its lead drug product.
INCY earnings call for the period ending September 30, 2019.
For Immediate ReleaseChicago, IL –November 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
The biotechnology industry has lagged the S&P 500 so far this year, but most of the industry participants haven’t disappointed investors. The above-average performance of...
Investors might want to bet on Incyte (NASDAQ:INCY), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1M||Current|
|Bullish Engulfing||1M||1||Oct 19|
|Three Outside Up||1H||1||Nov 13, 2019 10:00AM|
|Bullish Engulfing||1H||2||Nov 13, 2019 09:00AM|
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.